drugset
drugset / Trial / NCT01427933

A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer

NCT01427933 ↗

Phase 2 Completed 141 enrolled Eli Lilly and Company
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a study to compare the antitumor activity of ramucirumab (IMC-1121B) and eribulin together versus eribulin alone, in participants with locally recurrent or metastatic breast cancer.

Timeline

Start
2011-11
Primary completion
2013-09
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Ramucirumab Monoclonal antibody 10 mg/kg Intravenous
Background Eribulin Small molecule 1.4 mg/m2 Intravenous

Indications

breast cancer